Plural Concentric Cores Patents (Class 424/471)
  • Patent number: 11236098
    Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: February 1, 2022
    Assignee: Purdue Pharma L.P.
    Inventors: Robert Chapman, Lonn S. Rider, Qi Hong, Robert Kupper, Donald J. Kyle
  • Patent number: 11229577
    Abstract: The present invention relates to a process for the preparation of a solid pharmaceutical administration form using a 3D printing process as well. The process is a printing process that allows the production of solid pharmaceutical administration forms in a flexible manner and in conformity with the high quality standards required for the production of pharmaceuticals.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: January 25, 2022
    Assignee: Merck Patent GmbH
    Inventors: Stefan Schiller, Andrea Hanefeld, Gerhard Jonschker
  • Patent number: 11202767
    Abstract: The present invention provides methods for the treatment of urea cycle disorders and Maple Syrup Urine Disease.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: December 21, 2021
    Assignee: Acer Therapeutics Inc.
    Inventors: Leah E. Appel, Joshua R. Shockey, D. Christopher Schelling
  • Patent number: 10987311
    Abstract: Extended release pyridostigmine dosage forms, suitable for maintaining stable plasma concentrations with reduced or minimized initial burst release/dose dumping of pyridostigmine, are provided. The dosage forms include matrix tablets, gastroretentive tablets, and pellets, the latter being suitable for dosing in capsules, tablets, and sachets, as well as for sprinkling on foodstuffs. The disclosure also provides methods for improving patient compliance by administering once-a-day extended release pyridostigmine bromide dosage forms that provide a superior controlled drug release.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: April 27, 2021
    Assignee: KASHIV SPECIALTY PHARMACEUTICALS, LLC
    Inventors: Siva Ram Kiran Vaka, Namdev B. Shelke, Dipen Desai, Wantanee Phuapradit, Navnit H. Shah
  • Patent number: 10966944
    Abstract: Administration of a salt of bicyclo [2.2.2] octane-2-carbonic acid reduces dysphoria in dysphoric subjects, ameliorates ethanol craving in alcoholics, reduces the erythrocyte sedimentation rate and the level of liver function markers (AST, ALT, and bilirubin) in human subjects, and reduces the number or strength of seizures in epileptics.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: April 6, 2021
    Inventor: Susanna A. Saakian
  • Patent number: 10933072
    Abstract: Provided herein are compositions, systems, and methods for treating a disease, such as kidney and/or cardiovascular disease, with an agent that reduces the production of trimethylamine (TMA) or trimethylamine-n-oxide (TMAO) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (DMB) or a DMB derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and/or cecum); iii) a flavin monooxygenase 3 (FMO3) inhibitor; iv) a gut TMA lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a TMA and/or TMAO sequestering agent.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: March 2, 2021
    Assignee: The Cleveland Clinic Foundation
    Inventor: Stanley L. Hazen
  • Patent number: 10807995
    Abstract: The present invention provides compounds useful for the treatment of opioid dependence, alcohol dependence, alcohol use disorder, or the prevention of relapse to opioid dependence in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: October 20, 2020
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Brian M. Aquila, Hoan Huynh, Lewis D. Pennington, Ingo Mugge, Baudouin Gerard, Markus Haeberlein, Roman A. Valiulin, Julius F. Remenar, Demetri T. Moustakas, Thomas Andrew Wynn, Todd Bosanac
  • Patent number: 10765635
    Abstract: Various embodiments of modified-release multiparticulates (in bead or granule from) are described. The modified-release multiparticulates can comprise a core including a pharmaceutical and/or probiotic agent, optionally with additional excipients or binders to aid in creation of the core, one or more functional coatings disposed on the core and configured to provide a modified-release profile of the pharmaceutical and/or probiotic agent when given orally, and a coating of hypromellose acetate succinate (HPMCAS) disposed on the one or more functional coatings and configured to impart multiparticulate stability in aqueous acidic media. Suspensions including the modified-release multiparticulates are also described.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: September 8, 2020
    Inventors: Robert Niichel, Samuel Reinhold, III, Clayton J. Nelsen, Dan A. Finkbeiner, Roy J. McDaniel, Andrew D. Padilla
  • Patent number: 10758577
    Abstract: The present invention is directed to compositions comprising a mixture of microbes and the metabolites produced when the microbes are grown together. The invention is further directed to methods for making and using the compositions.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: September 1, 2020
    Assignee: PURE CULTURES 2020, INC.
    Inventors: Steven K. Kazemi, Naseer Sangwan
  • Patent number: 10751307
    Abstract: Administration of a salt of bi-cyclo [2.2.2] octane-2-carbonic acid reduces dysphoria in dysphoric subjects, ameliorates ethanol craving in alcoholics, reduces the erythrocyte sedimentation rate and the level of liver function markers (AST, ALT, and bilirubin) in human subjects, and reduces the number or strength of seizures in epileptics.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: August 25, 2020
    Inventor: Susanna A. Saakian
  • Patent number: 10695267
    Abstract: The present disclosure relates to medical devices containing time-release drug substance, and more particularly, to medical tubing, catheters, stents, cables (including fiber optic cables), pills, capsules, sheaths, threads, clamps, sutures, and endotracheal devices. The invention also generally relates to a method for extruding multiple laminated flow streams using microlayer coextrusion to create these various time-release drug delivery products.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: June 30, 2020
    Assignee: Guill Tool & Engineering Co., Inc.
    Inventors: Richard R. Guillemette, Robert G. Peters, Christopher Hummel
  • Patent number: 10632073
    Abstract: This invention relates to a granulate comprising mannitol and sorbitol in a weight ratio of between 70:30 and 97:3. This invention also relates to the use of the said granulate in the preparation of orodispersible tablets, to the orodispersible tablets obtained with the said granulate and to a process of production for obtaining the said granulate.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: April 28, 2020
    Assignee: E-PHARMA TRENTO S.p.A.
    Inventors: Massimiliano Rossi, Riccardo Catalano, Silvia Boschetti, Paolo Andreatta
  • Patent number: 10507185
    Abstract: A composite structural material and pharmaceutical composition comprising same, the use of the composite structural material in preparing a sustained release formulation, and a pharmaceutical composition formulation method; the composite structural material comprises a hydrophobic structural material and a hydrophilic structural material; the proportion of the hydrophobic structural material to the hydrophilic structural material ranges from 1:0.01 to 1:5, preferably 1:0.05 to 1:4, more preferably 1:0.1 to 1:3, and most preferably 1:0.4 to 1:2, such as 1:0.4 to 1:1.3. The pharmaceutical composition comprises the composite structural material and one or more active pharmaceutical ingredients, and preferably the proportion of the composite structural material to the active pharmaceutical ingredients ranges from 1:0.01 to 1:8, more preferably 1:0.02 to 1:5, and most preferably 1:0.03 to 1:1, such as 1:0.3 to 1:0.7.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: December 17, 2019
    Assignee: INNOVACO PHARMACEUTICALS, INC.
    Inventors: William Shifeng Wei, Herling Uang
  • Patent number: 10434138
    Abstract: The present invention relates to a formulation comprising a pharmaceutically active ingredient and a coating. The invention also relates to the use of the formulation in the treatment and prevention of disorders of the gastrointestinal tract. Also disclosed are methods for preparing the formulations.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: October 8, 2019
    Assignee: Sublimity Therapeutics Limited
    Inventors: Ivan Coulter, Vincenzo Aversa, Mónica Rosa, Bernard Francis McDonald
  • Patent number: 10226430
    Abstract: Delayed release of a drug to the colon is achieved from a delayed release formulation comprising a core and a coating for the core. The core comprises a drug and the coating comprises an inner layer and an outer layer. The outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria, and a second polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a third polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said third polymeric material being selected from an at least partially neutralized polycarboxylic acid and a non-ionic polymer. In embodiments in which the third polymeric material is a non-ionic polymer, the inner layer comprises at least one of a buffer agent and a base.
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: March 12, 2019
    Assignee: TILLOTTS PHARMA AG
    Inventors: Roberto Carlos Bravo Gonzalez, Thomas Buser, Frederic Jean-Claude Goutte, Abdul Waseh Basit, Felipe Jose Oliveira Varum, Ana Cristina Freire
  • Patent number: 10098866
    Abstract: A stabilized preparation which comprises: a unstable drug in a polyethylene glycol-containing preparation; and a coating agent comprising a copolyvidone instead of polyethylene glycol with which the drug is coated.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: October 16, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Hajime Ishida, Makoto Fukuta
  • Patent number: 10098835
    Abstract: A multi-step method of making a mammalian subcutaneous medical implant or non-implant for releasing self-contained drugs on a controlled basis over at least a 3 day period includes depositing at least portions of one or more individual layers of the implant by at least one computer controlled 3-D printer. The 3-D printing method may be accomplished via an array of 3-D nozzles that deposit materials (such as plastics, thermoplastics, coating materials, drug-containing matrix materials, non-drug containing matrix materials, bonding materials, biodegradable materials and/or the like) in very small, precise portions. The materials may be deposited in liquid, powder, sheet or other forms. Non-implant forms may also be provided by the techniques disclosed herein.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: October 16, 2018
    Inventors: Robert W. Adams, Wayne C. Pollock
  • Patent number: 9730899
    Abstract: The invention relates to a controlled release pharmaceutical composition, comprising a core, comprising a pharmaceutical active ingredient, whereby the core is coated by an ethanol resistance conferring coating layer which has the effect of conferring the release profile of the pharmaceutical active ingredient to be resistant against the influence of ethanol, whereby the ethanol resistance conferring coating layer comprises at least 70% by weight of a mixture of a polymeric portion a) and an excipients portion b), with the polymeric portion a) is consisting of a water insoluble essentially neutral vinyl polymer or vinyl copolymer and the excipients portion b) is consisting of the excipients b1) 100 to 250% by weight of a non-porous inert lubricant, b2) 1 to 35% by weight of a cellulosic compound, b3) 0.1 to 25% by weight of an emulsifier and additionally or alternatively to b3), b4) 0.
    Type: Grant
    Filed: March 18, 2009
    Date of Patent: August 15, 2017
    Assignee: Evonik Roehm GmbH
    Inventors: Hans Bär, Thomas Fürst, Gerhard Renner, Michael Gottschalk
  • Patent number: 9616057
    Abstract: Compositions and methods are provided for inhibiting or treating the early and established stages of inflammatory diseases by administration of an effective dose of the desethylhydroxychloroquine (DHCQ). A benefit of the methods is the ability to deliver a dose of agent that is effective in treating inflammation while sparing the individual from retinal toxicity.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 11, 2017
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The United States of America as Represented by the Department of Veterans Affairs
    Inventors: William H. Robinson, Jeremy Sokolove, Qian Wang
  • Patent number: 9592203
    Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: March 14, 2017
    Assignee: COSMO TECHNOLOGIES LIMITED
    Inventors: Roberto Villa, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati
  • Patent number: 9446009
    Abstract: The biodegradable drug delivery systems described here are formulated for implantation into the nail unit and its surrounding tissues for the treatment of various nail unit conditions. The systems include non-temperature dependent phase change compositions that may be formulated as solutions, solids, semisolids, microparticles, or crystals.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: September 20, 2016
    Assignee: Hallux, Inc.
    Inventors: Frank Kochinke, Corinne Bright
  • Patent number: 9404162
    Abstract: According to the invention there is provided a strain of lactic acid bacteria of the genus Bifidobacteria obtainable by isolation from resected and washed feline gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Bifidobacteria of the present invention are also provided.
    Type: Grant
    Filed: April 18, 2008
    Date of Patent: August 2, 2016
    Assignee: MARS, INCORPORATED
    Inventors: Thomas William-Maxwell Boileau, Barry Pius Kiely, Liam Diarmuid O'Mahony, John MacSharry, Greg Dean Sunvold
  • Patent number: 9339489
    Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 10 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: May 17, 2016
    Assignee: Aprecia Pharmaceuticals Company
    Inventors: Jules Jacob, Norman Coyle, Thomas G West, Donald C. Monkhouse, Henry L. Surprenant, Nemichand B. Jain
  • Patent number: 9333177
    Abstract: The present invention relates to a novel liquid delivery carrier comprising a specific grade of glyceryl caprylate and PEG-40 hydrogenated castor oil in particular amounts. This carrier can be loaded with slightly or poorly water soluble substances and filled into hard gelatin capsule shells for final administration to a subject. Also disclosed are filling compositions comprising such delivery carrier and hard gelatin capsules filled with the carrier and the composition of the invention. The delivery carrier of the invention proved to be compatible with both the hard gelatin capsule shells and the substances loaded into it.
    Type: Grant
    Filed: October 26, 2010
    Date of Patent: May 10, 2016
    Assignee: Capsugel Belgium NV
    Inventors: David Delmarre, Marie-Sophie Lina Martina, Jan Emiel Godelieve Vertommen
  • Patent number: 9283192
    Abstract: In one aspect, the present invention is concerned with a treatment where it is desired that an active agent is designed to be released in a prolonged manner at a time point some time after administration of the active agent. The present invention is particularly suited to administering an agent which may be released whilst a subject is sleeping, shortly before waking and continues to administer the drug during the early waking hours. As well as treating certain conditions by a particular regime, the invention also provides novel formulations for a delayed, followed by a prolonged release of drug.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: March 15, 2016
    Assignee: UNIVERSITY OF STRATHCLYDE
    Inventors: Alexander Mullen, Howard Stevens, Sarah Eccleston
  • Patent number: 9283304
    Abstract: A biocompatible metallic material may be configured into any number of implantable medical devices, including intraluminal stents. The biocompatible metallic material may comprise a magnesium alloy. The magnesium alloy implantable medical device may be designed to degrade over a given period of time. In order to control the degradation time, the device may be coated or otherwise have affixed thereto one or more coatings, one of which comprises a material for controlling the degradation time and maintain a pH neutral environment proximate the device. Additionally, therapeutic agents may be incorporated into one or more of the coatings on the implantable medical device.
    Type: Grant
    Filed: November 25, 2008
    Date of Patent: March 15, 2016
    Assignee: CARDINAL HEALTH SWITZERLAND 515 GmbH
    Inventor: Jonathon Z. Zhao
  • Patent number: 9248095
    Abstract: A multi-part nutritional supplement system supplies nutrients to a user at advantageous locations in the digestive tract. One type of dosage unit is formulated to release vitamin B12 in the stomach and intestines of the upper GI tract, advantageously in an amount that is greater than or at multiple levels of the DV (Daily Value) of vitamin B12.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: February 2, 2016
    Assignee: Shaklee Corporation
    Inventors: Kuei-tu Chang, Carsten R. Smidt, John Castillo, William J. Mergens
  • Patent number: 9192177
    Abstract: According to the invention there is provided a strain of lactic acid bacteria of the genus Lactobacilli obtainable by isolation from resected and washed feline gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Lactobacilli of the present invention are also provided.
    Type: Grant
    Filed: April 18, 2008
    Date of Patent: November 24, 2015
    Assignee: The Iams Company
    Inventors: Thomas William-Maxwell Boileau, Barry Pius Kiely, Liam Diarmuid O'Mahony, John MacSharry, Greg Dean Sunvold
  • Patent number: 9173860
    Abstract: The present intervention generally relates to compositions comprising S-isomer of alpha-methyl-hydrocinnamic acid for the treatment and/or prevention of blood disorders and blood deficiencies, as well as methods for treating blood disorders and/or blood deficiency in a subject by administering a composition comprising S-isomer of alpha-methyl-hydrocinnamic acid to the subject to ameliorate at least one symptom associated with the blood disorder. Another aspect relates to administration of an S-isomer of alpha-methyl-hydrocinnamic acid stimulate multi-lineage hematopoietic cell production in a subject, for example, increasing the numbers of circulating neutrophils, erythrocytes and platelets. Accordingly, one aspect of the present invention relates to administration of S-isomer of alpha-methyl-hydrocinnamic acid, e.g., by oral administration to a subject for the treatment of blood disorders, for example but not limited to, hemaglobinaphthy, thalassemia and aplastic anemia.
    Type: Grant
    Filed: November 4, 2010
    Date of Patent: November 3, 2015
    Inventors: Susan Park Perrine, Douglas V. Faller
  • Patent number: 9107819
    Abstract: A controlled release pharmaceutical dosage form for controlled release of an active ingredient, includes an active ingredient coated by a polymeric mixture of: at least a water insoluble polymer; and at least an indigestible water-soluble oligosaccharide. The use and method of making the same are also described.
    Type: Grant
    Filed: October 27, 2009
    Date of Patent: August 18, 2015
    Assignee: ROQUETTE FRERES
    Inventors: Olaf Haeusler, Daniel Wils, Juergen Siepmann, Youness Karrout
  • Publication number: 20150125524
    Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.
    Type: Application
    Filed: October 16, 2014
    Publication date: May 7, 2015
    Applicant: Pozen Inc.
    Inventor: John R. PLACHETKA
  • Publication number: 20150079169
    Abstract: The present invention provides for novel formulations of clopidogrel in combination with proton pump inhibitors (PPI) and optionally with NSAIDs, for use as improved antiplatelet therapies in stroke and cardiovascular indications. The invention provides the delivery of clopidogrel in pulses or waves, such that the total dose is phased/spread out over time and, advantageously, combined with omeprazole in a way to minimize the conflicting actions these two drugs may have on each other. In addition, the invention also provides the delivery of clopidogrel and a PPI, and optionally aspirin, in a sequential (orderly) manner that would allow for the delivery and metabolism of clopidogrel first, followed by the PPI, and thereafter optionally aspirin. A particular mode of the invention involves the combination of clopidogrel with coformulated immediate release omeprazole+enteric coated aspirin.
    Type: Application
    Filed: September 14, 2012
    Publication date: March 19, 2015
    Applicant: POZEN INC.
    Inventor: John R. Plachetka
  • Publication number: 20150072005
    Abstract: Provided are methods for enhancing the efficacy of aspirin. Also provided are methods for reducing pain or preventing or treating heart attack, stroke or blood clot in a subject in need thereof. The methods entail orally administering to the subject a first composition comprising a first amount of aspirin, and a second composition comprising a second amount of aspirin, wherein the first composition is formulated so as to, upon administration, disintegrate or dissolve intraorally providing rapid release of the aspirin of the first composition in the subject, and wherein the second composition is formulated to be substantially more difficult than the first composition to disintegrate or dissolve intraorally but is ingestible and releasable in the gastrointestinal track of the subject. The method can further include administering to the subject a painkiller or an agent suitable for treating a cardiovascular disease or condition.
    Type: Application
    Filed: September 10, 2013
    Publication date: March 12, 2015
    Inventor: Joseph P. Habboushe
  • Patent number: 8962022
    Abstract: The present invention is directed to compositions of taste-masked microparticles comprising a substituted benzhydrylpiperazine coated and a taste-masking layer comprising a water-insoluble polymer and a gastrosoluble polymer, and methods of making such taste-masked microparticles. The present invention is also directed to stable orally disintegrating compositions comprising taste-masked microparticles of a substituted benzhydrylpiperazine and rapidly dispersing granules, and methods of making such orally disintegrating compositions.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: February 24, 2015
    Assignee: Aptalis Pharmatech, Inc.
    Inventor: Gopi Venkatesh
  • Publication number: 20150010625
    Abstract: A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.
    Type: Application
    Filed: September 24, 2014
    Publication date: January 8, 2015
    Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
  • Patent number: 8889187
    Abstract: An antibiotic product is comprised of at least two dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as one or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: November 18, 2014
    Assignee: Shionogi Inc.
    Inventors: Edward M Rudnic, James D Isbister, Donald J Treacy, Jr., Sandra E Wassink
  • Patent number: 8877247
    Abstract: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.
    Type: Grant
    Filed: February 22, 2010
    Date of Patent: November 4, 2014
    Assignee: Alpharma Pharmaceuticals LLC
    Inventors: Frank Matthews, Garth Boehm, Lijuan Tang, Alfred Liang
  • Publication number: 20140212489
    Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.
    Type: Application
    Filed: April 3, 2014
    Publication date: July 31, 2014
    Applicant: Pozen Inc.
    Inventor: John R. PLACHETKA
  • Patent number: 8778397
    Abstract: A method of making a pharmaceutical composition containing tolterodine L-tartrate stabilized against degradation with an acid. Acid-stabilized tolterodine L-tartrate may be used as an active ingredient in various types of immediate release and controlled release dosage forms, including tablets, capsules, and beads.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: July 15, 2014
    Assignee: Mylan, Inc.
    Inventors: David T. Rossi, Boyong Li, James Paul McCall
  • Patent number: 8765179
    Abstract: The invention relates to processes for coating a surface with a crosslinked polyelectrolytes multilayer film incorporating a protein, preferably a growth factor type protein. The invention also relates to crosslinked polyelectrolytes multilayer films obtained by this process, and a coated surface obtained therefrom.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: July 1, 2014
    Assignees: Institut Polytechnique de Grenoble, Universite Montpellier 2 Sciences et Techniques, Centre National de la Recherche Scientifique
    Inventors: Catherine Picart, Thomas Crouzier
  • Patent number: 8758817
    Abstract: Dosage forms for oral administration of the magnesium salt of (S)-pantoprazole are described.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: June 24, 2014
    Assignee: Takeda GmbH
    Inventors: Rango Dietrich, Isabel Anstett-Klein, Marc Schiller, Hartmut Ney, Manfred Hartmann, Sabine Schäfer-Preuss
  • Patent number: 8747820
    Abstract: The biodegradable drug delivery systems described here are formulated for implantation into the nail unit and its surrounding tissues for the treatment of various nail unit conditions. The systems include non-temperature dependent phase change compositions that may be formulated as solutions, solids, semisolids, microparticles, or crystals.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: June 10, 2014
    Assignee: Hallux, Inc.
    Inventors: Frank Kochinke, Corinne Bright
  • Publication number: 20140141080
    Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.
    Type: Application
    Filed: October 3, 2013
    Publication date: May 22, 2014
    Applicant: Pozen Inc.
    Inventor: John R. PLACHETKA
  • Patent number: 8703191
    Abstract: Controlled-release tablets exhibiting excellent storage stability are achieved by granulating a pharmaceutically active agent with a hydroxyalkylcelluose, blending the resulting granules with an extragranular phase composed of a particulate material that provides a sustained-release matrix, and compressing the blend into a tablet form, which may be optionally coated, such as with an enteric coating composition, to provide delayed release and/or to enhance stability of the active agent.
    Type: Grant
    Filed: July 25, 2007
    Date of Patent: April 22, 2014
    Assignee: Intelgenx Corp.
    Inventors: Horst G. Zerbe, Nadine Paiement
  • Patent number: 8703192
    Abstract: Dosage forms for the oral administration of the magnesium salt of pantoprazole are described.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: April 22, 2014
    Assignee: Takeda GmbH
    Inventors: Isabel Anstett-Klein, Rango Dietrich, Hartmut Ney, Marc Schiller, Sabine Schaefer-Preuss, Manfred Hartmann
  • Patent number: 8703186
    Abstract: An opioid-antagonist oral dosage form which does not release a therapeutically effective amount of the opioid antagonist when the oral dosage form is orally administered to a human being, but whereby a physical alteration of the oral dosage form results in a release of the therapeutically effective amount of the opioid antagonist. An embodiment of the oral dosage form includes an opioid-antagonist layer coated onto a biologically inert pellet, and a non-releasing membrane coated onto the opioid-antagonist layer. Optionally, the oral dosage form can also include an opioid agonist, such that a method of preventing the abuse of an oral dosage form of an opioid agonist is provided by forming the oral dosage form including an opioid agonist and an opioid antagonist.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: April 22, 2014
    Assignee: Elite Laboratories, Inc.
    Inventor: Atul M. Mehta
  • Publication number: 20140037723
    Abstract: A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.
    Type: Application
    Filed: October 8, 2013
    Publication date: February 6, 2014
    Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
  • Publication number: 20140004189
    Abstract: Modified release pharmaceutical compositions of memantine or pharmaceutically acceptable salts thereof are described. The compositions of invention are stable, possess improved formulation characteristics and also provide extended therapeutically effective plasma levels over a twenty four hours period. Processes of making these compositions are also described.
    Type: Application
    Filed: January 25, 2012
    Publication date: January 2, 2014
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Sunilendu Bhushan Roy, Sushrut Krishnaji Kulkarni, Sandhya Rajendra Shenoy, Imran Shakoor Ghogari, Vijaykumar Shivajrao Patil
  • Patent number: 8591870
    Abstract: The biodegradable drug delivery systems described here are formulated for implantation into the nail unit and its surrounding tissues for the treatment of various nail unit conditions. The systems include non-temperature dependent phase change compositions that may be formulated as solutions, solids, semisolids, microparticles, or crystals.
    Type: Grant
    Filed: January 6, 2011
    Date of Patent: November 26, 2013
    Assignee: Hallux, Inc.
    Inventors: Frank Kochinke, Corinne Bright
  • Patent number: 8535715
    Abstract: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: September 17, 2013
    Assignees: Bristol-Myers Squibb Company, AstraZeneca UK Limited
    Inventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Divyakant Desai, Peter Timmins